* Sellas Life Sciences Group Inc SLS.OQ SLS.O is
expected
to show no change in quarterly revenue when it reports
results on November 7 (estimated) for the period ending
September 30 2024
*
* LSEG's mean analyst estimate for Sellas Life Sciences
Group Inc
is for a loss of 13 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Sellas Life
Sciences Group Inc is 6.00, above its last closing price
of $1.18.
This summary was machine generated November 6 at 13:55 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)